Compare BBW & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBW | LYEL |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.5M | 556.1M |
| IPO Year | 2004 | 2021 |
| Metric | BBW | LYEL |
|---|---|---|
| Price | $38.57 | $22.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $67.71 | $30.60 |
| AVG Volume (30 Days) | ★ 326.0K | 75.9K |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | ★ 3.99 | N/A |
| Revenue | ★ $357,866,000.00 | $36,000.00 |
| Revenue This Year | $5.63 | N/A |
| Revenue Next Year | $4.62 | $8,712.13 |
| P/E Ratio | $9.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.10 | $0.39 |
| 52 Week High | $75.77 | $45.00 |
| Indicator | BBW | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 47.92 |
| Support Level | $38.37 | $22.38 |
| Resistance Level | $40.16 | $26.89 |
| Average True Range (ATR) | 1.42 | 1.62 |
| MACD | 0.53 | 0.07 |
| Stochastic Oscillator | 59.36 | 33.41 |
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments. Its Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, China, Denmark, Ireland, and the U.K., including the company's e-commerce sites and temporary stores. The international franchising segment includes the licensing activities of the company's franchise agreements with store locations in Europe, Asia, Australia, the Middle East, and Africa. The commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.